Production (Stage)
4D Molecular Therapeutics, Inc.
FDMT
$3.49
-$0.11-3.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.06% | -53.86% | -327.49% | -18.02% | -12.97% |
| Total Depreciation and Amortization | 10.04% | 17.91% | 21.99% | 13.73% | 12.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.48% | 5.24% | -6.64% | -20.78% | 35.90% |
| Change in Net Operating Assets | -103.72% | -659.94% | 173.18% | -150.63% | 21.62% |
| Cash from Operations | -64.18% | -86.06% | -2,409.91% | -37.06% | -4.24% |
| Capital Expenditure | 11.13% | -72.86% | -339.01% | 56.65% | 29.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.41% | 230.57% | -4.30% | -246.11% | -694.78% |
| Cash from Investing | 112.14% | 205.64% | -8.94% | -249.20% | -710.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -87.38% | -94.33% | -86.83% | 2,781.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -87.38% | -94.62% | -86.78% | 2,800.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -159.69% | -43.78% | -103.87% | -154.86% | 1.02% |